RET and non-small cell lung carcinoma: As of December 2022 (as presented at AACR in 2023, [46]), 31 RET fusion–positive NSCLC patients received HS10365 at 6 doses (40 mg QD to 200 mg BID), including 25 who had previously received platinum-based chemotherapy and 6 treatment-naïve patients.